EU/3/16/1712

About

On 29 August 2016, orphan designation (EU/3/16/1712) was granted by the European Commission to Galapagos NV, Belgium, for 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-alpha]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile for the treatment of idiopathic pulmonary fibrosis.

Key facts

Active substance
2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-alpha]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile
Disease / condition
Treatment of idiopathic pulmonary fibrosis
Date of first decision
29/08/2016
Outcome
Positive
EU designation number
EU/3/16/1712

Review of designation


The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Galapagos N.V.
Generaal De Wittelaan L11 A3
2800 Mechelen Antwerp
Belgium
Tel. +32 1534 2900
E-mail: medicalinfo@glpg.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating